Embark Showcase 2025: Featuring Endios Bio's Wendy Overton and PI Alexandra Whiteley

Wendy Overton CEO, Endios Bio

Alexandra Whiteley Assistant Professor, Biochemistry

Connecting entrepreneurs with breakthrough innovations. Embark is the CU Boulder's deep tech startup creator for matching entrepreneurs with breakthrough innovations. With myriad CU Boulder technologies ready to make a real-world impact, Embark seeks motivated entrepreneurs ready to launch new companies. The program provides IP rights, salary support, grant funds, startup acceleration resources and investor introductions to selected entrepreneurs.

At the recent annual Embark Deep Tech Startup Creator Showcase, Wendy Overton, in her role as an Embark 2024-25Entrepreneur in Residence, presented the opportunities and the science behind Endios Bio. Alexandra Whiteley is the PI on Endios Bio's science and her scientific exploration of gene peg10 is helping Endios develop breakthrough therapeutics for rare neurodegenerative diseases such as ALS and Angelmans.

Endios Bio

CEO: Wendy Overton
PI: Alexandra Whiteley (CU Boulder Biochemistry)

Endios Bio is developing breakthrough therapeutics for rare neurodegenerative diseases by targeting the newly discovered impacts of the gene peg10, which was recently linked to ALS and Angelmans and has druggable potential. Visit the Endios Website